Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930621 | 0.98 | LOXL2 (0.42) | LOXLOXL2CXCR4CSNK2A1GRM5 | |
| SCHEMBL507961 | 0.79 | CSNK2A1 (0.46) | LOXLOXL2CSNK2A1HRH3CARM1 | |
| SCHEMBL16839498 | 0.78 | TRPA1 (0.43) | GRM5KDM4EL3MBTL1LNPEPHRH3 | |
| SCHEMBL508795 | 0.77 | CSNK2A1 (0.47) | LOXLOXL2CSNK2A1HRH3CARM1 | |
| SCHEMBL507751 | 0.76 | CXCR4 (0.40) | LOXLOXL2CXCR4CYP1A2CYP2D6 | |
| SCHEMBL2585954 | 0.75 | LOX (0.61) | LOXLOXL2CSNK2A1HRH3 | |
| SCHEMBL508574 | 0.74 | PDGFRB (0.40) | LOXLOXL2CXCR4CYP1A2CYP2D6 | |
| SCHEMBL4929130 | 0.73 | KMT2A (0.43) | LOXLOXL2CXCR4CSNK2A1LNPEP | |
| SCHEMBL18616251 | 0.72 | HRH3 (0.50) | LOXLOXL2CSNK2A1HRH3CARM1 | |
| SCHEMBL4962479 | 0.72 | CARM1 (0.48) | GRM5HRH3CARM1PRMT6DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1924561-B1 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR1A, HTR2A | LOX 3137/4885LOXL2 3376/4885CXCR4 1375/4885 |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR1A, HTR2A | LOX 3137/4885LOXL2 3376/4885CXCR4 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.